Press Release: DataVault AI and Wellgistics Health Announce Plans for PharmacyChain™ to Implement Manufacturer-to-Patient Blockchain-enabled Smart Contracts for the Prescription Drug Industry to Improve Efficiency and Patient Outcomes
BEAVERTON, Ore., Oct. 22, 2025 (GLOBE NEWSWIRE) -- via IBN -- DataVault AI, Inc. (“DataVault”) (NASDAQ: DVLT), leading the way in AI data experience, valuation, and monetization, and Wellgistics Health, Inc. ("Wellgistics") (NASDAQ: WGRX), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced the two companies have entered into…
SINGAPORE, April 19, 2026 (GLOBE NEWSWIRE) -- SQRIL, the leading cross-border QR code payment infrastructure for emerging markets, today announced its official expansion into Africa. Starting today, SQRIL’s API enables users to perform seamless stablecoin-to-fiat QR code transactions across Tanzania, Kenya, and South Africa, marking a major leap in financial interoperability for the continent.
VANCOUVER, British Columbia and BOSTON, MA, April 19, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today presented positive data from the Phase 3 X-TOLE2 study highlighting the efficacy and safety of azetukalner in focal…
NEW YORK, April 19, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Pinterest, Inc. (NYSE: PINS) between February 7, 2025 and February 12, 2026, inclusive, (the “Class Period”), of the important May 29, 2026 lead plaintiff deadline.
NEW YORK, April 19, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Coty Inc. (NYSE: COTY) and certain of its officers.
EDMONTON, Alberta , April 19, 2026 (GLOBE NEWSWIRE) -- Fedora Pharmaceuticals, Inc., a leader in the development of drugs to treat antibiotic-resistant infections, is presenting a full suite of preclinical findings from the company’s lead candidate, FPI-2119 at the European Society of Clinical Microbiology and Infectious Diseases Congress (ESCMID) in Munich, Germany. Presentations at ESCMID…